|
| Status |
Public on Apr 15, 2024 |
| Title |
A phase II randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
Other
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| Submission date |
Sep 14, 2023 |
| Last update date |
Apr 15, 2024 |
| Contact name |
Stephanie Osmond |
| E-mail(s) |
sosmond@benaroyaresearch.org
|
| Organization name |
Benaroya Research Institute
|
| Street address |
1201 9th Ave
|
| City |
Seattle, |
| State/province |
WA |
| ZIP/Postal code |
98101 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
| GPL30173 |
NextSeq 2000 (Homo sapiens) |
|
| Samples (117)
|
|
| This SuperSeries is composed of the following SubSeries: |
| GSE243201 |
Maintenance of beta cell function in adolescent T1D subjects treated with a single dose of polyclonal expanded Treg is linked to lower ex vivo Treg expansion |
| GSE243270 |
Response to Treg therapy is linked to rate of ex vivo Treg expansion |
|
| Relations |
| BioProject |
PRJNA1017509 |
Less...
More...